Ochs J J, Freeman A I, Douglass H O, Higby D S, Mindell E R, Sinks L F
Cancer Treat Rep. 1978 Feb;62(2):239-45.
Eight patients with advanced metastatic osteogenic sarcoma were treated with cis-dichlorodiammineplatinum(II) (DDP). Prior to DDP, seven patients had amputations and all had received adjuvant adriamycin (ADR) therapy. In addition, prior to DDP, six patients had received high-dose methotrexate. There was one complete response (pulmonary metastases) and four partial responses (three metastases in the lungs and one in the bone). One additional patient, with local recurrence of osteogenic sarcoma of the mandible following initial resection and adjuvant ADR, was retreated with surgery and DDP and is disease-free for greater than 3 years. The cumulative dose ranged from 300 to 660 mg/m2. Toxicity included irreversible kidney damage in two patients, transient severe hematologic suppression in two patients, and nausea and vomiting in all patients. DDP is a new effective agent in the treatment of osteogenic sarcoma.
8例晚期转移性骨肉瘤患者接受了顺二氯二氨铂（DDP）治疗。在使用DDP之前，7例患者接受了截肢手术，且均接受过阿霉素（ADR）辅助治疗。此外，在使用DDP之前，6例患者接受过高剂量甲氨蝶呤治疗。有1例完全缓解（肺转移灶），4例部分缓解（3例肺转移和1例骨转移）。另有1例患者，最初切除并接受ADR辅助治疗后下颌骨骨肉瘤局部复发，再次接受手术和DDP治疗，无病生存期超过3年。累积剂量范围为300至660mg/m²。毒性反应包括2例患者出现不可逆的肾损害，2例患者出现短暂的严重血液学抑制，所有患者均有恶心和呕吐症状。DDP是治疗骨肉瘤的一种新的有效药物。
